Gleevec Tablet
Product Images NDC 0078-0649
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gleevec (NDC 0078-0649). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 Progression Free Survival (itt Principle) (Gleevec 02)
Figure 2 Time To Progression To Ap Or Bc (itt Principle) (Gleevec 03)
Figure 3: Study 1 Recurrence-free Survival (itt Population) (Gleevec 04)
Figure 4: Study 2 Recurrence-free Survival (itt Population) (Gleevec 05)
Figure 5: Study 2 Overall Survival (itt Population) (Gleevec 06)
Ndc 0078-0401-34 Rx Only Gleevec® (imatinib Mesylate) Tablets 100 mg Each Tablet Contains 119.5 mg Of Imatinib Mesylate Equivalent To 100 mg Of Imatinib Free Base. 90 Tablets Novartis (Gleevec 07)
Ndc 0078-0649-13 Rx Only Gleevec® (imatinib Mesylate) Tablets 400 mg Per Tablet Each Tablet Contains 478 mg Of Imatinib Mesylate Equivalent To 400 mg Of Imatinib Free Base. 30 Tablets Novartis (Gleevec 08)
Ndc 0078-1490-13 Rx Only Gleevec® (imatinib Mesylate) Tablets 400 mg Per Tablet Each Tablet Contains 478 mg Of Imatinib Mesylate Equivalent To 400 mg Of Imatinib Free Base. 30 Tablets Novartis (Gleevec 09)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.